Ibrutinib (BTKi) and niclosamide (STAT3i) did not show a consistent increased toxicity in the ATRX-deficient glioma cells as compared to their ATRX-proficient counterparts (Figure S3E,F), suggesting that the sensitivity of ATRX-deficient cells to these inhibitors may be influenced by other factors. Here, ATRX is linked to central nervous system cancer.